FindTrial
Sign In

Empegfilgrastim

DRUG2 trials

Sponsors

Biocad, Moscow Clinical Scientific Center

Conditions

Breast CancerGastrointestinal CancerGynecological MalignanciesHigh-Risk CancerMyelosuppressionPatients With Solid Tumours Who Receive Myelosupressive TherapySolid Tumor

Unknown Phase

DEFENDOR: A Multicenter Prospective Observational Post-registration stuDy of Extimia® (INN: empEgfilrastim) to Evaluate Efficacy and saFEty in patieNts With soliD tumORs
NCT04811443
BiocadPatients With Solid Tumours Who Receive Myelosupressive Therapy
Start: 2021-01-12End: 2022-06-12Target: 500Updated: 2021-03-23
A Multicenter Prospective Post-registration Study of Empegfilgrastim to Evaluate Safety and Efficacy in Special Cancer Populations
NCT04905329
Moscow Clinical Scientific CenterBreast Cancer, Gastrointestinal Cancer, Gynecological Malignancies +3
Start: 2020-04-28End: 2023-09-01Target: 285Updated: 2021-06-02

Related Papers

Efficacy of neoadjuvant TCHP with primary empegfilgrastim (E) prophylaxis in HER2-positive early breast cancer (HER2+ eBC): Final results of the DEFENDOR SPECIAL study.
Journal of Clinical Oncology2026-05-28
Efficacy of neoadjuvant TCHP regimen with empegfilgrastim in early HER2-positive breast cancer: Final analysis of the DEFENDOR SPECIAL study, HER2+ BC cohort
Journal of Modern Oncology2026-04-08
DEFENDOR SPECIAL: Effect of primary prophylaxis with empegfilgrastim on pCR rate after neoadjuvant TCHP in early HER2+ breast cancer patients—Matching-adjusted indirect comparison (MAIC).
Journal of Clinical Oncology2025-05-28
Abstract 5975: Long-acting G-CSF empefilgrastim with dose-dense chemotherapy for patients with stage II-III TNBC: Defendor Special trial, primary analysis
Cancer Research2025-04-21
Defendor special: Interim analysis of TCHP with primary empegfilgrastim prophylaxis (long-acting G-CSF) for treatment outcomes in early HER2+ breast cancer.
Journal of Clinical Oncology2023-06-011 citations
Abstract P3-07-23: Defendor Special: Primary empegfilgrastim prophylaxis (prolonged G-CSF) for optimal treatment outcomes in high risk early breast cancer cohort. The interim analysis
Cancer Research2023-03-012 citations
Defendor: Real-world evidence of primary prolonged G-CSF prophylaxis by empegfilgrastim for relative dose intensity compliance in patients with solid tumors—The primary analysis.
Journal of Clinical Oncology2022-06-013 citations